Objective To investigate the effect of hepatocyte transplantation(HCT) in the treatment of rats with liver cirrhosis and small-for-size syndrome(SFSS).Methods A total of 40 male Sprague-Dawley rats were given subcutaneous injection of carbon tetrachloride and oral administration of alcohol to establish a rat model of liver cirrhosis, among which 30 were randomly selected and divided into group A(hepatocyte transplantation on day 3 before surgery), group B(hepatocyte transplantation during surgery), and group C(no hepatocyte transplantation), with 10 rats in each group. All rats were given the resection of 70% of the liver, and the groups were compared in terms of survival rate, blood biochemistry at different time points, and change in liver pathological section based on HE staining. An analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant differencet-test(for data with homogeneity of variance) or the Games-Howell test(for data with heterogeneity of variance) was used for further comparison between two groups; the log-rank test was used for comparison of survival rate.Results Group A had a significantly higher postoperative survival rate than groups B and C [90%(9/10) vs 50%(5/10) and 30%(3/10),χ2= 6. 440,P= 0. 04]. For groups A, B, and C at/L,904.6 ±35.6 U respectively(F =6.808,P=0. 007), the meal level of aspartate aminotransferase(AST) was 896. 3 ± 44. 7 U/L, 923. 8 ± 31. 6 U/L, and950.0 ±16.3 U/L, respectively(F= 3. 666,P= 0. 047), and the mean level of albumin(Alb) was 25. 6 ± 0. 5 g/L, 24. 8 ± 0. 6 g/L,and 23.4 ±0.4 g/L, respectively(F =26.577,P< 0. 001); group A tended to have better recovery than groups B and C, while some/L,128.2 ±20.7 U/L, and 150.5 ±14.8 U/L, respectively(F =13.816,P= 0. 001), the mean level of AST was 108. 7 ± 10. 8 U/L, 142 0±14.1 U/L, and 161.0 ±21.2 U/L, respectively(F =17.220,P< 0. 001), and the mean level of Alb was 29. 1 ± 0. 6 g/L, 28. 0 ± 0 2 g/L, and 27.0 ±0.2 g/L, respectively(F =15.629,P= 0. 001), with significant differences between the three groups. At 72 hours after surgery, liver histopathological examination showed disappearance of hepatic cord, massive hepatocyte necrosis, and inflammatory cell infil-tration in group C, while group A only had balloon-like lesions, punctate cell necrosis, and a small amount of inflammatory cell infiltra-tion.Conclusion Hepatocyte transplantation can effectively promote liver function recovery and improve survival rate of rats with liver cir-rhosis and SFSS, and its therapeutic effect is associated with the time point of transplantation.
[1] FLOHR TR, BONATTI H Jr, BRAYMAN KL, et al. The use of stem cells in liver disease[J]. Curr Opin Organ Transplant,2009, 14(1):64-71.
|
[2] MAI RY, YE JZ, BAI T, et al. Advances in the prevention and treatment of posthepatectomy liver failure in patients with primary liver cancer[J]. J Clin Hepatol, 2018, 34(12):2685-2692.(in Chinese)麦荣云,叶甲舟,白涛,等.原发性肝癌肝切除术后肝衰竭的防治进展[J].临床肝胆病杂志,2018, 34(12):2685-2692.
|
[3] IBARS EP, CORTES M, TOLOSA L, et al. Hepatocyte transplantation program:Lessons learned and future strategies[J].World J Gastroenterol, 2016, 22(2):874-886.
|
[4] SOLTYS KA, SETOYAMA K, TAFALENG EN, et al. Host conditioning and rejection monitoring in hepatocyte transplantation in humans[J]. J Hepatol, 2017, 66(5):987-1000.
|
[5] DHAWAN A, STROM SC, SOKAL E, et al. Human hepatocyte transplantation[J]. Methods Mol Biol, 2010, 640:525-534.
|
[6] NICOLAS CT, WANG Y, NYBERG SL. Cell therapy in chronic liver disease[J]. Curr Opin Gastroenterol, 2016, 32(3):189-194.
|
[7] CARDOSO L, MOREIRA L, PINTO MA, et al. Domino hepatocyte transplantation:A therapeutic alternative for the treatment of acute liver failure[J]. Can J Gastroenterol Hepatol, 2018,2018:2593745.
|
[8] ANDERSON TN, ZARRINPAR A. Hepatocyte transplantation:Past efforts, current technology, and future expansion of therapeutic potential[J]. J Surg Res, 2018, 226:48-55.
|
[9] TANAKA K, OGURA Y.“Small-for-size graft” and “smallfor-size syndrome” in living donor liver transplantation[J].Yonsei Med J, 2004, 45(6):1089-1094.
|
[10] KIUCHI T, TANAKA K, ITO T, et al. Small-for-size graft in living donor liver transplantation:How far should we go?[J].Liver Transpl, 2003, 9(9):s29-s35.
|
[11] GOLRIZ M, ASHRAFI M, KHAJEH E, et al. Establishing a porcine model of small for size syndrome following liver resection[J]. Can J Gastroenterol Hepatol, 2017, 2017:5127178.
|
[12] PAN GD, YAN LN. Problems in adult living donor liver transplantation using the right hepatic lobe[J]. Hepatobiliary Pancreat Dis Int, 2006, 5(3):345-349.
|
[13] XU XL, WANG ZX, ZHOU Y, et al. Reconsideration of liver failure after liver cancer surgery[J]. J Clin Hepatol, 2018, 34(9):2008-2011.(in Chineae)许晓磊,王志鑫,周灜,等.对肝癌术后肝衰竭的再认识[J].临床肝胆病杂志,2018, 34(9):2008-2011.
|
[14] CHEN XP, XIANG S, HUANG ZY. Investigation of extent of liver resection for liver cancer combined with liver cirrhosis[J].Chin J Dig Surg, 2019, 18(4):303-306.(in Chineae)陈孝平,项帅,黄志勇.肝癌合并肝硬化肝切除范围的探讨[J].中华消化外科杂志,2019, 18(4):303-306.
|
[15] XU Y, REN ZH, YU ZM, et al. Role of somatostatin in protecting small-for-size liver after hepatectomy in rats with cirrhosis[J]. Chin J Hepatobiliary Surg, 2017, 23(8):542-547.(in Chinese)徐勇,任祖海,俞照妹,等.生长抑素对肝硬化大鼠肝切除术后小体积肝的保护作用[J].中华肝胆外科杂志,2017, 23(8):542-547.
|
[16] LI XC, WANG HW, LI CX. Present situation and prospect of comprehensive treatment of hepatocellular carcinoma[J].chin J Dig Surg, 2018, 17(5):433-436.(in Chinese)李相成,王宏伟,李长贤.肝癌综合治疗的现状与展望[J].中华消化外科杂志,2018, 17(5):433-436.
|